The genito urinary system and sex hormones market sales in Türkiye exhibited steady growth, defined by a consistent year-on-year increase. In 2023, the market stood at 1.06 billion USD PPP. Moving into 2024, forecasted sales reach 1.08 billion USD PPP, further increasing to 1.1 billion in 2025, 1.12 billion in 2026, 1.13 billion in 2027, and 1.15 billion in 2028. Percentage variations observed year-on-year reveal: 1.89% (2023 to 2024), 1.85% (2024 to 2025), 1.82% (2025 to 2026), 0.89% (2026 to 2027), and 1.77% (2027 to 2028). Over the five-year period (2023-2028), the compound annual growth rate (CAGR) stands at approximately 1.63%.
Future trends to watch for in this market include the impact of emerging biomedical innovations, demographic shifts such as aging populations, and policy changes in the healthcare sector. Additionally, economic factors and healthcare spending capabilities will be crucial in shaping the market’s trajectory. Strategic planning by pharmaceutical companies to meet these market dynamics will be vital for sustaining growth.
